Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Can Topical Drugs Help Prevent Breast Cancer? December 4, 2018 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma August 24, 2020 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 Load more HOT NEWS FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Breast Cancer Patients with Low Breast Density May Be More Likely... Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung...
